公开(公告)号：US20220324863A1

公开(公告)日：2022-10-13

申请号：US17744432

申请日：2022-05-13

Applicant: NOVARTIS AG

Inventor： Jan Jiricek ,  Isabelle K. Lerario ,  Fang Liang ,  Xiaodong Liu ,  Valentina Molteni ,  Advait Suresh Nagle ,  Shuyi Pearly NG ,  Maxim Ratnikov ,  Jeffrey M. Smith ,  Yongping Xie

IPC: C07D471/04 ,  A61P33/02 ,  C07D519/00

Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US10596175B2

公开(公告)日：2020-03-24

申请号：US16116418

申请日：2018-08-29

Applicant: NOVARTIS AG

Inventor： Agnes Biggart ,  Fang Liang ,  Casey Jacob Nelson Mathison ,  Valentina Molteni ,  Advait Suresh Nagle ,  Frantisek Supek ,  Vince Yeh

IPC: C07D487/04 ,  A61K31/519 ,  C07D519/00 ,  C07F5/02 ,  C07F7/08 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US11384078B2

公开(公告)日：2022-07-12

申请号：US16615749

申请日：2018-05-29

Applicant: NOVARTIS AG

Inventor： Jan Jiricek ,  Isabelle K. Lerario ,  Fang Liang ,  Xiaodong Liu ,  Valentina Molteni ,  Advait Suresh Nagle ,  Shuyi Pearly Ng ,  Maxim Ratnikov ,  Jeffrey M. Smith ,  Yongping Xie

IPC: A61K31/7048 ,  A61K31/541 ,  A61K31/197 ,  A61K31/155 ,  A61K31/555 ,  A61K31/417 ,  C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  A61P33/02

Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11123348B2

公开(公告)日：2021-09-21

申请号：US16780628

申请日：2020-02-03

Applicant: NOVARTIS AG

Inventor： Agnes Biggart ,  Fang Liang ,  Casey Jacob Nelson Mathison ,  Valentina Molteni ,  Advait Suresh Nagle ,  Frantisek Supek ,  Vince Yeh

IPC: A61K31/519 ,  C07D487/04 ,  C07D519/00 ,  C07F5/02 ,  C07F7/08 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US10085989B2

公开(公告)日：2018-10-02

申请号：US15600183

申请日：2017-05-19

Applicant: NOVARTIS AG

Inventor： Agnes Biggart ,  Fang Liang ,  Casey Jacob Nelson Mathison ,  Valentina Molteni ,  Advait Suresh Nagle ,  Frantisek Supek ,  Vince Yeh

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/695 ,  A61K31/5377

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.